Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • COVID-19 aggravates antibiotic misuse in India

    The COVID-19 catastrophe in India has resulted in more than 30 million people infected with the virus and nearly 400,000 deaths, though experts are concerned that the figures most likely are much higher. Meanwhile, another public health crisis has emerged along with COVID-19: the widespread misuse of antibiotics.

  • The viruses can kill cancer cells, unveils good viruses concept
    The viruses can kill cancer cells, unveils good viruses concept

    Researchers from the Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the LIH Department of Oncology (DONC) are working on the development of novel anticancer strategies based on oncolytic viruses, “good” viruses that can specifically infect, replicate in and kill cancer cells. In particular, the LOVIT team elucidated the mechanism through which the H-1PV cancer-destroying virus can attach to and enter cancer cells, thereby causing their lysis and death.

  • Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19
    Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19

    Cipla Limited, Dr. Reddy’s Laboratories Ltd, Emcure Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited and Torrent Pharmaceuticals Limited announced that the five companies will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India.

  • AI based start-up Niramai raised funding from CDC group
    AI based start-up Niramai raised funding from CDC group

    Niramai Health Analytix, a Deeptech health startup raised research funding from impact investor CDC for NIRAMAI FeverTest, which was launched last year.

    With leveraging of computer vision and AI to analyze and monitor crowd compliance to COVID-19 guidelines, NIRAMAI FeverTest’s smart software enables screening for COVID-19 symptoms in public places.

  • Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim
    Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

    Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

  • Sandoz to launch ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer in Europe
    Sandoz to launch ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer in Europe

    Sandoz announced the launch of generic oncology treatment Pemetrexed in 11 countries across Europe, including Germany, Switzerland, Netherlands, and Spain.

    Pemetrexed, as a monotherapy or in combination with cisplatin, is indicated for first-line, second-line and maintenance treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, and for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

  • Grand Prize Winner Announced in USD 5M IBM Watson AI XPRIZE Competition
    Grand Prize Winner Announced in USD 5M IBM Watson AI XPRIZE Competition

    XPRIZE, the worlds leader in designing and operating incentive competitions to solve humanitys grand challenges, and IBM Watson, IBMs AI technology for business, today announced the Grand Prize Winner in the USd 5M IBM Watson AI XPRIZE Challenge. First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.

  • Sun Pharma Announces Settlement of Patent Litigation for Generic Revlimid (lenalidomide) in US
    Sun Pharma Announces Settlement of Patent Litigation for Generic Revlimid (lenalidomide) in US

    Sun Pharmaceutical Industries Limited along with one of its wholly owned subsidiaries announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid® (lenalidomide capsules) in the US.

  • LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
    LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

    Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.

  • Zydus and Bayer announce continuity of their successful Joint Venture
    Zydus and Bayer announce continuity of their successful Joint Venture

    Bayer Pte Ltd and Cadila Healthcare Limited announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.

Subscribe to Pharma News